Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1992;85:1380-1389

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thery, C.
Right arrow Articles by Coquart, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thery, C.
Right arrow Articles by Coquart, J. P.

Circulation, Vol 85, 1380-1389, Copyright © 1992 by American Heart Association


ARTICLES

Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study

C Thery, G Simonneau, G Meyer, O Helenon, F Bridey, C Armagnac, P d'Azemar and JP Coquart
Hopital Cardiologique, Lille, France.

BACKGROUND. We compared the efficacy and safety of different dosages of a low-molecular-weight heparin, CY 216 D (Fraxiparine), in the treatment of submassive pulmonary embolism with unfractionated heparin in a prospective, randomized, dose-finding study. METHODS AND RESULTS. The primary outcome was the evolution of pulmonary vascular obstruction. We enrolled 101 patients. Four patient groups were formed: standard heparin by continuous intravenous infusion (group 1) and Fraxiparine subcutaneously 400, 600, and 900 anti-Xa Institute Choay units/kg, respectively (groups 2, 3, and 4). Inclusions were stopped prematurely in groups 3 and 4 because of the incidence of major bleedings. At day 8, the improvement of the pulmonary vascular obstruction and the major bleedings were similar in groups 1 and 2. CONCLUSIONS. The Fraxiparine dosage of 400 anti-Xa Institute Choay units/kg is as effective and safe as unfractionated heparin in the treatment of submassive pulmonary embolism.


This article has been cited by other articles:


Home page
ChestHome page
C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota
Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 454S - 545S.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
T. A. Morris, S. Castrejon, G. Devendra, and A. C. Gamst
No Difference in Risk for Thrombocytopenia During Treatment of Pulmonary Embolism and Deep Venous Thrombosis With Either Low-Molecular-Weight Heparin or Unfractionated Heparin: A Metaanalysis
Chest, October 1, 2007; 132(4): 1131 - 1139.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. Aujesky, K. J. Smith, J. Cornuz, and M. S. Roberts
Cost-Effectiveness of Low-Molecular-Weight Heparin for Treatment of Pulmonary Embolism
Chest, September 1, 2005; 128(3): 1601 - 1610.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
D. J. Quinlan, A. McQuillan, and J. W. Eikelboom
Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism: A Meta-Analysis of Randomized, Controlled Trials
Ann Intern Med, February 3, 2004; 140(3): 175 - 183.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. E. Dalen
Pulmonary Embolism: What Have We Learned Since Virchow?: Treatment and Prevention
Chest, November 1, 2002; 122(5): 1801 - 1817.
[Full Text] [PDF]


Home page
HeartHome page
M. Riedel
VENOUS THROMBOEMBOLIC DISEASE: Acute pulmonary embolism 2: treatment
Heart, March 1, 2001; 85(3): 351 - 360.
[Full Text]


Home page
Arch Intern MedHome page
M. Meignan, J. Rosso, H. Gauthier, F. Brunengo, S. Claudel, L. Sagnard, P. d'Azemar, G. Simonneau, and B. Charbonnier
Systematic Lung Scans Reveal a High Frequency of Silent Pulmonary Embolism in Patients With Proximal Deep Venous Thrombosis
Arch Intern Med, January 24, 2000; 160(2): 159 - 164.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
P. S C Wong, S. P Singh, R. D S Watson, and G. Y H Lip
Management of pulmonary thrombo-embolism using catheter manipulation: a report of four cases and review of the literature
Postgrad. Med. J., December 1, 1999; 75(890): 737 - 742.
[Abstract] [Full Text]


Home page
ANN INTERN MEDHome page
M. K. Gould, A. D. Dembitzer, R. L. Doyle, T. J. Hastie, and A. M. Garber
Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Meta-Analysis of Randomized, Controlled Trials
Ann Intern Med, May 18, 1999; 130(10): 800 - 809.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
H. Bounameaux
Unfractionated versus low-molecular-weight heparin in the treatment of venous thromboembolism
Vascular Medicine, February 1, 1998; 3(1): 41 - 46.
[Abstract] [PDF]


Home page
NEJMHome page
G. Simonneau, H. Sors, B. Charbonnier, Y. Page, J.-P. Laaban, R. Azarian, M. Laurent, J.-L. Hirsch, E. Ferrari, J.-L. Bosson, et al.
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Acute Pulmonary Embolism
N. Engl. J. Med., September 4, 1997; 337(10): 663 - 669.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
E. E. Weinmann and E. W. Salzman
Deep-Vein Thrombosis
N. Engl. J. Med., December 15, 1994; 331(24): 1630 - 1641.
[Full Text]


Home page
JWatch GeneralHome page
LOW-MOLECULAR-WEIGHT HEPARIN FOR THROMBOSIS
Journal Watch (General), April 21, 1992; 1992(421): 1 - 1.
[Full Text]